Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Clinical trial NCT01695941 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01695941
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2012-08-31
Primary completion: 2018-05-29
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.